JP2013544811A - 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物 - Google Patents

自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物 Download PDF

Info

Publication number
JP2013544811A
JP2013544811A JP2013537774A JP2013537774A JP2013544811A JP 2013544811 A JP2013544811 A JP 2013544811A JP 2013537774 A JP2013537774 A JP 2013537774A JP 2013537774 A JP2013537774 A JP 2013537774A JP 2013544811 A JP2013544811 A JP 2013544811A
Authority
JP
Japan
Prior art keywords
phenyl
trifluoromethyl
isoxazol
chroman
oxadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2013537774A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544811A5 (enExample
Inventor
ロバート・ジェイ・チャーニー
ワン・ジョンギュ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2013544811A publication Critical patent/JP2013544811A/ja
Publication of JP2013544811A5 publication Critical patent/JP2013544811A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013537774A 2010-11-03 2011-11-02 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物 Ceased JP2013544811A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40968210P 2010-11-03 2010-11-03
US61/409,682 2010-11-03
PCT/US2011/058891 WO2012061459A1 (en) 2010-11-03 2011-11-02 Heterocyclic compounds as s1p1 agonists for the treatment of autoimmune and vascular diseases

Publications (2)

Publication Number Publication Date
JP2013544811A true JP2013544811A (ja) 2013-12-19
JP2013544811A5 JP2013544811A5 (enExample) 2014-11-06

Family

ID=44983720

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013537774A Ceased JP2013544811A (ja) 2010-11-03 2011-11-02 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物

Country Status (6)

Country Link
US (1) US8629282B2 (enExample)
EP (1) EP2635573B1 (enExample)
JP (1) JP2013544811A (enExample)
CN (1) CN103298807A (enExample)
ES (1) ES2525298T3 (enExample)
WO (1) WO2012061459A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023502355A (ja) * 2019-11-20 2023-01-24 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を処置する方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012012477A1 (en) 2010-07-20 2012-01-26 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
MA40082B1 (fr) 2014-08-20 2019-09-30 Bristol Myers Squibb Co Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme
RU2754845C2 (ru) * 2016-07-22 2021-09-08 Медшайн Дискавери Инк. Агонист s1p1 и его применение
EP3638235A4 (en) 2017-06-14 2021-06-09 Trevena, Inc. COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING IT
CN111683946B (zh) * 2018-01-18 2022-04-05 南京明德新药研发有限公司 一种三并环化合物的晶型、盐型及其制备方法
JP2023502123A (ja) * 2019-11-19 2023-01-20 トレベナ・インコーポレイテッド Ｓ１ｐ１モジュレーター化合物及び化合物を調製する方法

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007088450A2 (en) * 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2009080728A1 (en) * 2007-12-21 2009-07-02 Glaxo Group Limited Oxadiazole derivatives active on sphingosine-1-phosphate (sip)
WO2009131090A1 (ja) * 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
WO2010069949A1 (en) * 2008-12-18 2010-06-24 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
WO2010072352A1 (en) * 2008-12-26 2010-07-01 Almirall S.A. 1, 2, 4 -oxadiazole derivatives and their therapeutic use
WO2010081692A1 (en) * 2009-01-19 2010-07-22 Almirall, S.A. Oxadiazole derivatives as slpl receptor agonists
WO2010085584A1 (en) * 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
WO2010085581A1 (en) * 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2010085582A1 (en) * 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2011017578A1 (en) * 2009-08-07 2011-02-10 Bristol-Myers Squibb Company Sphingosine-1-phosphate receptor agonists

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4200750A (en) 1977-01-07 1980-04-29 Westwood Pharmaceuticals Inc. 4-Substituted imidazo [1,2-a]quinoxalines
US6069143A (en) 1994-12-20 2000-05-30 Smithkline Beecham Corporation Fibrinogen receptor antagonists
CA2472713C (en) 2002-01-18 2011-07-19 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
US7479504B2 (en) 2002-01-18 2009-01-20 Merck & Co., Inc. Edg receptor agonists
AU2003216054B2 (en) 2002-01-18 2007-01-04 Merck & Co., Inc. Selective S1P1/Edg1 receptor agonists
AU2003217764A1 (en) 2002-03-01 2003-09-16 Merck & Co., Inc. Aminoalkylphosphonates and related compounds as edg receptor agonists
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
CN1788008A (zh) * 2003-05-15 2006-06-14 麦克公司 作为s1p受体激动剂的3－(2－氨基－1－氮杂环基)－5－芳基－1,2,4－噁二唑
ES2467160T3 (es) 2003-05-19 2014-06-12 Irm Llc Compuestos y composiciones inmunosupresores
AU2004277947A1 (en) * 2003-10-01 2005-04-14 Merck & Co., Inc. 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as S1P receptor agonists
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
US7659294B2 (en) 2004-10-22 2010-02-09 Merck & Co., Inc. 2-(aryl)azacyclylmethyl carboxylates, sulfonates, phosphonates, phosphinates and heterocycles as S1P receptor agonists
DE602006003642D1 (en) 2005-03-23 2008-12-24 Actelion Pharmaceuticals Ltd Neue thiophen-derivate als sphingosin-1-phosphat-1-rezeptorantagonisten
TW200642683A (en) 2005-04-22 2006-12-16 Sankyo Co Heterocyclic compound
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
CN101291908A (zh) 2005-08-23 2008-10-22 Irm责任有限公司 免疫抑制剂化合物和组合物
TW200806633A (en) 2006-03-21 2008-02-01 Epix Pharm Inc S1P receptor modulating compounds and use thereof
PT2003132E (pt) 2006-04-03 2014-05-26 Astellas Pharma Inc Derivados de oxadiazole como agonistas dos s1p1
JP2009269819A (ja) 2006-08-25 2009-11-19 Asahi Kasei Pharma Kk アミン化合物
HRP20130180T1 (hr) 2006-09-08 2013-03-31 Actelion Pharmaceuticals Ltd. Derivati piridin-3-ila kao sredstva imunomodulacije
GB0625648D0 (en) 2006-12-21 2007-01-31 Glaxo Group Ltd Compounds
AU2008227979B2 (en) 2007-03-16 2014-02-06 Actelion Pharmaceuticals Ltd Amino- pyridine derivatives as S1P1 /EDG1 receptor agonists
CA2696863C (en) 2007-10-04 2016-10-18 Anna Quattropani Oxadiazole derivatives
JP5517944B2 (ja) 2007-11-01 2014-06-11 アクテリオン ファーマシューティカルズ リミテッド 新規なピリミジン誘導体
MX336881B (es) 2009-10-29 2016-02-04 Bristol Myers Squibb Co Compuestos heterociclicos triciclicos.
US8835470B2 (en) 2010-04-23 2014-09-16 Bristol-Myers Squibb Company Mandelamide heterocyclic compounds
WO2012012477A1 (en) 2010-07-20 2012-01-26 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
EP2619190B1 (en) 2010-09-24 2015-08-12 Bristol-Myers Squibb Company Substituted oxadiazole compounds and their use as s1p1 agonists

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007088450A2 (en) * 2006-02-01 2007-08-09 Pfizer Products Inc. Chromane antagonist of the h-3 receptor
WO2009080728A1 (en) * 2007-12-21 2009-07-02 Glaxo Group Limited Oxadiazole derivatives active on sphingosine-1-phosphate (sip)
WO2009131090A1 (ja) * 2008-04-21 2009-10-29 旭化成ファーマ株式会社 アミノ酸化合物
WO2010069949A1 (en) * 2008-12-18 2010-06-24 Merck Serono S.A. Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis
WO2010072352A1 (en) * 2008-12-26 2010-07-01 Almirall S.A. 1, 2, 4 -oxadiazole derivatives and their therapeutic use
WO2010081692A1 (en) * 2009-01-19 2010-07-22 Almirall, S.A. Oxadiazole derivatives as slpl receptor agonists
WO2010085584A1 (en) * 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Pyrazole-i, 2, 4 -oxad iazole derivatives as s.phing0sine-1-ph0sphate agonists
WO2010085581A1 (en) * 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2010085582A1 (en) * 2009-01-23 2010-07-29 Bristol-Myers Squibb Company Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
WO2011017578A1 (en) * 2009-08-07 2011-02-10 Bristol-Myers Squibb Company Sphingosine-1-phosphate receptor agonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023502355A (ja) * 2019-11-20 2023-01-24 アリーナ ファーマシューティカルズ， インコーポレイテッド Ｓ１ｐ１受容体に関連する状態を処置する方法

Also Published As

Publication number Publication date
EP2635573A1 (en) 2013-09-11
ES2525298T3 (es) 2014-12-19
EP2635573B1 (en) 2014-10-01
WO2012061459A1 (en) 2012-05-10
US20130237566A1 (en) 2013-09-12
US8629282B2 (en) 2014-01-14
CN103298807A (zh) 2013-09-11

Similar Documents

Publication Publication Date Title
JP2013544811A (ja) 自己免疫疾患および血管疾患の治療用のｓ１ｐ１アゴニストとしての複素環式化合物
JP5728487B2 (ja) 三環式ヘテロ環化合物
EP2382212B1 (en) Substituted oxadiazole derivatives as s1p agonists in the treatment of autoimmune and inflammatory diseases
US8389509B2 (en) Substituted pyrazole compounds
JP5788507B2 (ja) 置換３−フェニル−１，２，４−オキサジアゾール化合物
US8404672B2 (en) Substituted heterocyclic compounds
ES2533095T3 (es) Agonistas de receptores de esfingosina-1-fosfato
CN103237795B (zh) 经取代的噁二唑化合物及其作为s1p1激动剂的用途
JP5735634B2 (ja) スフィンゴシン−１−リン酸受容体１アゴニストとしての４−（５−イソオキサゾリルまたは５−ピラゾリル−１，２，４−オキサジアゾール−３−イル）−マンデル酸アミド化合物
JP2019532917A (ja) 置換された三環式ヘテロ環化合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140917

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150714

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151014

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160407

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160816

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20161220